Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-010: pembrolizumab with or without lenvatinib as first-line treatment for PD-L1-selected recurrent or metastatic head and neck squamous cell carcinoma
2019-003717-34Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Pembrolizumab + lenvatinib with Pembrolizumab + placebo (2 arms). Primary endpoint: Objective Response Rate per RECIST 1.1 as assessed by BICR. Started Jan 2020; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-003717-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003717-34.